Literature DB >> 12093088

Intranuclear aggregation of nonexpanded ataxin-3 in marinesco bodies of the nonhuman primate substantia nigra.

Mattias Kettner1, Dirk Willwohl, Gene B Hubbard, U Rüb, Edward J Dick, Ann B Cox, Yvon Trottier, Georg Auburger, Heiko Braak, Christian Schultz.   

Abstract

Marinesco bodies (MB) are intranuclear inclusion bodies predominantly found in melanin-pigmented neurons of the substantia nigra. MB are demonstrable not only in humans but also in nonhuman primates. In the present study MB of aged rhesus monkeys (Macaca mulatta; n = 15; mean age 16 years) and aged baboons (Papio anubis; n = 13; mean age 25 years) were examined immunohistochemically. MB were found to be immunoreactive for ubiquitin, a protein involved in initiation of proteasome-mediated proteolysis. We also demonstrate that MB in monkeys are intensely immunoreactive for the protein ataxin-3 as detected by using two monoclonal anti-ataxin-3 antibodies (1H9 and 2B6). The abnormally expanded form of this polyglutamine protein is known to be causally involved in spinocerebellar ataxia type 3 or Machado-Joseph disease. The monoclonal antibody 1C2 was employed to examine whether ataxin-3 in MB in monkeys contains such an abnormally expanded polyglutamine stretch. MB were consistently 1C2-immunonegative, indicating that they are composed of normal wild-type ataxin-3. In conclusion MB in nonhuman primates permit experimental examination of mechanisms involved in transnuclear localization, intranuclear aggregation, and ubiquitination of nonexpanded polyglutamine proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093088     DOI: 10.1006/exnr.2002.7916

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

1.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

2.  Marinesco bodies and substantia nigra neuron density in Parkinson's disease.

Authors:  R D Abbott; J S Nelson; G W Ross; J H Uyehara-Lock; C M Tanner; K H Masaki; L J Launer; L R White; H Petrovitch
Journal:  Neuropathol Appl Neurobiol       Date:  2017-07-09       Impact factor: 8.090

3.  Distribution and pattern of pathology in subjects with familial or sporadic late-onset cerebellar ataxia as assessed by p62/sequestosome immunohistochemistry.

Authors:  Maria Pikkarainen; Päivi Hartikainen; Hilkka Soininen; Irina Alafuzoff
Journal:  Cerebellum       Date:  2011-12       Impact factor: 3.847

Review 4.  Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

Authors:  Kritika Raj; Ravi Shankar Akundi
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

5.  Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion.

Authors:  Charlotte A Scarff; Bruno Almeida; Joana Fraga; Sandra Macedo-Ribeiro; Sheena E Radford; Alison E Ashcroft
Journal:  Mol Cell Proteomics       Date:  2015-02-19       Impact factor: 5.911

6.  George Marinesco in the Constellation of Modern Neuroscience.

Authors:  Ioan Opris; Valeriu S Nestianu; Adrian Nestianu; Liviu Bilteanu; Jean Ciurea
Journal:  Front Neurosci       Date:  2017-12-25       Impact factor: 4.677

Review 7.  Research Relevant Conditions and Pathology in Nonhuman Primates.

Authors:  Chandra Saravanan; Thierry Flandre; Carolyn L Hodo; Anne D Lewis; Lars Mecklenburg; Annette Romeike; Oliver C Turner; Hsi-Yu Yen
Journal:  ILAR J       Date:  2020-12-31       Impact factor: 1.521

8.  The Spatial Organization of the Intranuclear Structures of Human Brain Dopaminergic Neurons.

Authors:  D E Korzhevskii; V V Gusel'nikova; O V Kirik; E G Sukhorukova; I P Grigorev
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.